a b s t r a c tWhen do short lead times warrant a cost premium? Decision makers generally agree that short lead times enhance competitiveness, but have struggled to quantify their benefits. Blackburn (2012) argued that the marginal value of time is low when demand is predictable and salvage values are high. de Treville et al. (2014) used real-options theory to quantify the relationship between mismatch cost and demand volatility, demonstrating that the marginal value of time increases with demand volatility, and with the volatility of demand volatility. We use the de Treville et al. model to explore the marginal value of time in three industrial supply chains facing relatively low demand volatility, extending the model to incorporate factors such as tender-loss risk, demand clustering in an order-up-to model, and use of a target fill rate that exceeded the newsvendor profit-maximizing order quantity. Each of these factors substantially increases the marginal value of time. In all of the companies under study, managers had underestimated the mismatch costs arising from lead time, so had underinvested in cutting lead times.
As the time between the decision about what to produce and the moment when demand is observed (the decision lead time) increases, the demand forecast becomes more uncertain. Uncertainty can increase gradually in decision lead time, or can increase as a dramatic change in median demand. Whether the forecast evolves gradually or in jumps has important implications for the value of responsiveness, which we model as the cost premium worth paying to reduce the decision lead time (the justified cost premium). Demand uncertainty arising from jumps rather than from constant volatility increases the justified cost premium when an average jump increases median demand, but decreases the justified cost premium when an average jump decreases median demand. We fit our model to two data sets, first publicly available demand data from Reebok, then point‐of‐sale data from a supermarket chain. Finally, we present two special cases of the model, one covering a sudden loss of demand, and the other a one‐time adjustment to median demand.
We consider a manufacturer without any frozen periods in production schedules so that it can dynamically update the schedules as the demand forecast evolves over time until the realization of actual demand. The manufacturer has a fixed production capacity in each production period, which impacts the time to start production as well as the production schedules. We develop a dynamic optimization model to analyze the optimal production schedules under capacity constraint and demand‐forecast updating. To model the evolution of demand forecasts, we use both additive and multiplicative versions of the martingale model of forecast evolution. We first derive expressions for the optimal base stock levels for a single‐product model. We find that manufacturers located near their market bases can realize most of their potential profits (i.e., profit made when the capacity is unlimited) by building a very limited amount of capacity. For moderate demand uncertainty, we also show that it is almost impossible for manufacturers to compensate for the increase in supply–demand mismatches resulting from long delivery lead times by increasing capacity, making lead‐time reduction a better alternative than capacity expansion. We then extend the model to a multi‐product case and derive expressions for the optimal production quantities for each product given a shared capacity constraint. Using a two‐product model, we show that the manufacturer should utilize its capacity more in earlier periods when the demand for both products is more positively correlated.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.